39P Determination of essential biomarkers in lung cancer: a real-world data study in Spain.
V. Calvo de Juan1, M. Cobo Dols2, D. Rodriguez-Abreu3, E. Carcereny4, A. Cantero5, R. Bernabé Caro6, G. Benitez Lopez3, R. Lopez Castro7, B. Massuti Sureda8, E. del Barco9, M.R. Garcia Campelo10, M. Guirado11, C.J.C. Camps Herrero12, A.L.O. Ortega Granados13, J.L. Gonzalez-Larriba14, A. Sanchez Hernandez15, C. Gonzalez Ojea16, M.A. Sala Gonzalez17, O.J. Juan Vidal18, M. Provencio Pulla1 [Text Wrapping Break]1Medical Oncology Department, University Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain, 2Medical Oncology, Biomedical Research Institute of Málaga (IBIMA), Malaga, Spain, 3Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain, 4National and Kapodistrian University & Frontier Science Foundation Hellas, Athens, Greece, 5Oncología Médica., Hospital Regional Universitario Málaga Carlos Haya, Malaga, Spain, 6Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain, 7Radiation And Medical Oncology Department, Hospital Clinico Universitario De Valladolid, Valladolid, Spain, 8Medical Oncology department, Hospital General Universitario de Alicante, Alicante, Spain, 9ONcology, HOSP. CLINICO UNIVERSITARIO SALAMANCA, Salamanca, Spain, 10Dept. Medical Oncology, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, 11Hospital General Universitario de Elche, Elche, Alicante, Spain, 12Hospital General Universitario Valencia, Valencia, Spain, 13Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Jaen, Spain, 14Medical Oncology department, Hospital Clinico Universitario San Carlos, Madrid, Spain, 15Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellon De La Plana, Spain, 16Hospital Universitario Alvaro Cunqueiro, Vigo, Pontevedra, Spain, 17Hospital Universitario de Basurto, Bilbao, Spain, 18Medical Oncology Dept., Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background: The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to date. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory.
Methods: To study the situation of biomarker testing in Spain.
Results: 9,239 patients diagnosed with stage IV non-small cell lung cancer (NSCLC) were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value <0.001). The global testing of EGFR, ALK, and ROS1 was 78.9%, 64.7%, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or PDL1.
Conclusions: Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing NGS in an integrated and cost-effective way in lung cancer.
Clinical trial identification: NCT02941458
Legal entity responsible for the study: FUNDACION GECP
Funding: Has not received any funding
Disclosure: All authors have declared no conflicts of interest.